Turning promise into progress for antiangiogenic agents in epithelial ovarian cancer

Critical Reviews in Oncology/Hematology

Volumn 84, Issue 2, 2012, Pages 224-242

  van der Bilt, Arne R M ^a   de Vries, Elisabeth G E ^a   de Jong, Steven ^a   Timmer Bosscha, Hetty ^a   van der Zee, Ate G J ^a   Reyners, Anna K L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Angiogenesis; Antiangiogenic therapy; Bevacizumab; Ovarian cancer; Patient selection; Tyrosine kinase inhibition; VEGF Trap

Indexed keywords

AFLIBERCEPT; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CABOZANTINIB; CAPECITABINE; CARBOPLATIN; CEDIRANIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NINTEDANIB; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TOPOTECAN;

ABDOMINAL PAIN; ADVANCED CANCER; ANTIANGIOGENIC THERAPY; ARTERIAL THROMBOEMBOLISM; ASCITES; BLEEDING; BLOOD CELL COUNT; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STAGING; COLORECTAL CANCER; CONSTIPATION; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INTERMITTENT THERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFUSION; FATIGUE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL OBSTRUCTION; GASTROINTESTINAL SYMPTOM; GRANULOCYTE COUNT; HAND FOOT SYNDROME; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPONATREMIA; LEUKOCYTE COUNT; LEUKOPENIA; LUNG CANCER; LYMPHOCYTOPENIA; MAINTENANCE THERAPY; METABOLIC DISORDER; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; NEUROPATHY; NEUTROPENIA; NOSE SEPTUM PERFORATION; OVARY CANCER; OVARY CARCINOMA; OVERALL SURVIVAL; PAIN; PARACENTESIS; PATIENT SELECTION; PROGRESSION FREE SURVIVAL; PROTEINURIA; RECURRENT CANCER; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SKIN DISEASE; STOMATITIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOSIS; TISSUE PRESSURE; TUMOR VASCULARIZATION; VASCULAR DISEASE; VENOUS THROMBOEMBOLISM; VOMITING;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS, GLANDULAR AND EPITHELIAL; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR;

EID: 84867886987     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.03.006     Document Type: Review

References (137)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61:69-90.
2. Bast R.C., Hennessy B., Mills G.B. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009, 9:415-428.
3. Bookman M.A., Brady M.F., McGuire W.P., et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009, 27:1419-1425.
4. Armstrong D.K., Bundy B., Wenzel L., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006, 354:34-43.
5. Spannuth W.A., Sood A.K., Coleman R.L. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008, 5:194-204.
6. Burger R.A., Brady M.F., Bookman M.A., et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
7. Perren T.J., Swart A.M., Pfisterer J., et al. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
8. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
9. Ferrara N., Kerbel R.S. Angiogenesis as a therapeutic target. Nature 2005, 438:967-974.
10. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000, 6:389-395.
11. Ferrara N., Gerber H.P., LeCouter J. The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
12. Tammela T., Zarkada G., Wallgard E., et al. Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. Nature 2008, 454:656-660.
13. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis 2006, 9:225-230.
14. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
15. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003, 9:677-684.
16. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
17. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000, 5(Suppl.):3-10.
18. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
19. Helmlinger G., Yuan F., Dellian M., Jain R.K. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
20. Morikawa S., Baluk P., Kaidoh T., Haskell A., Jain R.K., McDonald D.M. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160:985-1000.
21. Baluk P., Morikawa S., Haskell A., Mancuso M., McDonald D.M. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. Am J Pathol 2003, 163:1801-1815.
22. Ramakrishnan S., Subramanian I.V., Yokoyama Y., Geller M. Angiogenesis in normal and neoplastic ovaries. Angiogenesis 2005, 8:169-182.
23. Zeleznik A.J., Schuler H.M., Reichert L.E. Gonadotropin-binding sites in the rhesus monkey ovary: role of the vasculature in the selective distribution of human chorionic gonadotropin to the preovulatory follicle. Endocrinology 1981, 109:356-362.
24. Wulff C., Dickson S.E., Duncan W.C., Fraser H.M. Angiogenesis in the human corpus luteum: simulated early pregnancy by HCG treatment is associated with both angiogenesis and vessel stabilization. Hum Reprod 2001, 16:2515-2524.
25. Fraser H.M., Wilson H., Morris K.D., Swanston I., Wiegand S.J. Vascular endothelial growth factor Trap suppresses ovarian function at all stages of the luteal phase in the macaque. J Clin Endocrinol Metab 2005, 90:5811-5818.
26. Fraser H.M., Wilson H., Rudge J.S., Wiegand S.J. Single injections of vascular endothelial growth factor trap block ovulation in the macaque and produce a prolonged, dose-related suppression of ovarian function. J Clin Endocrinol Metab 2005, 90:1114-1122.
27. Duncan T.J., Al-Attar A., Rolland P., et al. Vascular endothelial growth factor expression in ovarian cancer: a model for targeted use of novel therapies?. Clin Cancer Res 2008, 14:3030-3035.
28. Van der Bilt AR, Van der Zee AG, De Vries EG, et al. Multiple VEGF family members are simultaneously expressed in ovarian cancer: a proposed model for bevacizumab resistance. Curr Pharm Des; in press.
29. Rudlowski C., Pickart A.K., Fuhljahn C., et al. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up. Int J Gynecol Cancer 2006, 16(Suppl.):183-189.
30. Yokoyama Y., Charnock-Jones D.S., Licence D., et al. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br J Cancer 2003, 88:237-244.
31. Boss E.A., Massuger L.F., Thomas C.M., Geurts-Moespot A., Boonstra H., Sweep C.G. Vascular endothelial growth factor in ovarian cyst fluid. Cancer 2001, 91:371-377.
32. Jeon B.H., Jang C., Han J., et al. Profound but dysfunctional lymphangiogenesis via vascular endothelial growth factor ligands from CD11b+ macrophages in advanced ovarian cancer. Cancer Res 2008, 68:1100-1109.
33. Birner P., Schindl M., Obermair A., Breitenecker G., Oberhuber G. Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001, 7:1661-1668.
34. Wong C., Wellman T.L., Lounsbury K.M. VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol Oncol 2003, 91:513-517.
35. Nishida N., Yano H., Komai K., Nishida T., Kamura T., Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 2004, 101:1364-1374.
36. Cannistra S.A., Matulonis U.A., Penson R.T., et al. Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. J Clin Oncol 2007, 25:5180-5186.
37. Burger R.A., Sill M.W., Monk B.J., Greer B.E., Sorosky J.I. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007, 25:5165-5171.
38. Smerdel M.P., Steffensen K.D., Waldstrøm M., Brandslund I., Jakobsen A. The predictive value of serum VEGF in multiresistant ovarian cancer patients treated with bevacizumab. Gynecol Oncol 2010, 118:167-171.
39. Escorcia F.E., Henke E., McDevitt M.R., et al. Selective killing of tumor neovasculature paradoxically improves chemotherapy delivery to tumors. Cancer Res 2010, 70:9277-9286.
40. Giantonio B.J., Catalano P.J., Meropol N.J., et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007, 25:1539-1544.
41. 11C-labeled docetaxel in patients with non-small cell lung cancer (NSCLC): implications for scheduling of antiangiogenic agents. J Clin Oncol 2011, 29(15S):3059.
42. Garcia A.A., Hirte H., Fleming G., et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008, 26:76-82.
43. McGonigle K.F., Muntz H.G., Vuky J.L., et al. Phase II prospective study of weekly topotecan and bevacizumab in platinum refractory ovarian cancer or peritoneal cancer (OC). J Clin Oncol 2008, 26(15S):5551.
44. Tillmanns T.D., Lowe M.P., Schwartzberg L.S., Walker M.S., Stepanski E.J. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma. J Clin Oncol 2010, 28(15S):5009.
45. Kudoh K., Takano M., Kouta H., et al. Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecol Oncol 2011, 122:233-237.
46. Del Carmen M.G., Micha J.P., Small L.A., Street D.G., Londhe A., McGowan T. Pegylated liposomal doxorubicin and carboplatin plus bevacizumab in patients with platinum sensitive recurrent ovarian Fallopian tube, or primary peritoneal cancers: results of a phase II study. J Clin Oncol 2011, 29(15S):5061.
47. Aghajanian C., Finkler N.J., Rutherford T., et al. OCEANS: a randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or Fallopian tube cancer (FTC). J Clin Oncol 2011, 29(18S):LBA5007.
48. Micha J.P., Goldstein B.H., Rettenmaier M.A., et al. A phase II study of outpatient first-line paclitaxel, carboplatin, and bevacizumab for advanced-stage epithelial ovarian, peritoneal, and Fallopian tube cancer. Int J Gynecol Cancer 2007, 17:771-776.
49. Rose P.G., Drake R., Braly P.S., et al. Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and Fallopian tube. J Clin Oncol 2009, 27(15S):5546.
50. Penson R.T., Dizon D.S., Cannistra S.A., et al. Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors. J Clin Oncol 2010, 28:154-159.
51. Burger RA, Brady MF, Bookman MA, et al. Phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or Fallopian tube cancer: a Gynecologic Oncology Group (GOG) study. Presentation at the annual meeting of the American Society of Clinical Oncology (ASCO); 2010. URL: http://www.asco.org/ASCOv2/MultiMedia/Virtual+Meeting%3F%26vmview=vm_session_presentations_view%26confID=74%26sessionID=3463.
52. Perren T, Swart AM, Pfisterer J, et al. ICON7: a phase III Gynaecologic Cancer InterGroup (GCIG) trial of adding bevacizumab to standard chemotherapy in women with newly diagnosed epithelial ovarian, primary peritoneal or Fallopian tube cancer. Presentation at the annual meeting of the European Society for Medical Oncology (ESMO); 2010. URL: http://www.ctu.mrc.ac.uk/icon7/content_pages/documents/ICON7_%20ESMO%20Presidential%20Presentation.pdf.
53. Stone R.L., Sood A.K., Coleman R.L. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol 2010, 11:465-475.
54. Hapani S., Chu D., Wu S. Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. Lancet Oncol 2009, 10:559-568.
55. Tanyi J.L., McCann G., Hagemann A.R., et al. Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecol Oncol 2011, 120:464-469.
56. Holash J., Davis S., Papadopoulos N., et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002, 99:11393-11398.
57. Byrne A.T., Ross L., Holash J., et al. Vascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer model. Clin Cancer Res 2003, 9:5721-5728.
58. Hu L., Hofmann J., Holash J., Yancopoulos G.D., Sood A.K., Jaffe R.B. Vascular endothelial growth factor trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model. Clin Cancer Res 2005, 11:6966-6971.
59. Coleman R.L., Duska L.R., Ramirez P.T., et al. Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol 2011, 12:1109-1117.
60. Tew W.P., Colombo N., Ray-Coquard I., et al. VEGF-Trap for patients (pts) with recurrent platinum-resistant epithelial ovarian cancer (EOC): preliminary results of a randomized, multicenter phase II study. J Clin Oncol 2007, 25(18S):5508.
61. Moroney J.W., Sood A.K., Coleman R.L. Aflibercept in epithelial ovarian cancer. Future Oncol 2009, 5:591-600.
62. Colombo N., Mangili G., Mammoliti S., et al. A phase II study of aflibercept in patients with advanced epithelial ovarian cancer and symptomatic malignant ascites. Gynecol Oncol 2012, [Epub ahead of print].
63. Gotlieb W.H., Amant F., Advani S., et al. Intravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Oncol 2012, 13:154-162.
64. Biagi J.J., Oza A.M., Chalchal H.I., et al. A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Ann Oncol 2011, 22:335-340.
65. Friedlander M., Hancock K.C., Rischin D., et al. A phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 2010, 119:32-37.
66. Hirte H.W., Vidal L., Fleming G.F., et al. A phase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritoneal or Fallopian tube cancer: final results of a PMH, Chicago and California consortia trial. J Clin Oncol 2008, 26(15S):5521.
67. Matulonis U.A., Berlin S., Ivy P., et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, Fallopian tube, and peritoneal cancer. J Clin Oncol 2009, 27:5601-5606.
68. Matei D., Sill M.W., Lankes H.A., et al. Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial. J Clin Oncol 2011, 29:69-75.
69. Welch S.A., Hirte H.W., Elit L., et al. Sorafenib in combination with gemcitabine in recurrent epithelial ovarian cancer: a study of the Princess Margaret Hospital Phase II Consortium. Int J Gynecol Cancer 2010, 20:787-793.
70. Kohn E.C., Lee J., Annunziata C.M., et al. A phase II study of intermittent sorafenib with bevacizumab in bevacizumab-naive epithelial ovarian cancer (EOC) patients. J Clin Oncol 2011, 29(15S):5019.
71. Ledermann J.A., Hackshaw A., Kaye S., et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol 2011, 29:3798-3804.
72. Karaman M.W., Herrgard S., Treiber D.K., et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008, 26:127-132.
73. Robinson D.R., Wu Y.M., Lin S.F. The protein tyrosine kinase family of the human genome. Oncogene 2000, 19:5548-5557.
74. Bodnar L., Górnas M., Szczylik C. Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study. Gynecol Oncol 2011, 123:33-36.
75. Azad N.S., Posadas E.M., Kwitkowski V.E., et al. Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity. J Clin Oncol 2008, 26:3709-3714.
76. Lee J.M., Sarosy G.A., Annunziata C.M., et al. Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. Br J Cancer 2010, 102:495-499.
77. Pölcher M., Eckhardt M., Coch C., et al. Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer. Cancer Chemother Pharmacol 2010, 66:203-207.
78. Ramasubbaiah R., Perkins S.M., Schilder J., et al. Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group. Gynecol Oncol 2011, 123:499-504.
79. Buckanovich R.J., Berger R., Sella A., et al. Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): results from a phase II randomized discontinuation trial (RDT). J Clin Oncol 2011, 29(15S):5008.
80. Shojaei F., Lee J.H., Simmons B.H., et al. HGF/c-Met acts as an alternative angiogenic pathway in sunitinib-resistant tumors. Cancer Res 2010, 70:10090-10100.
81. Jubb A.M., Harris A.L. Biomarkers to predict the clinical efficacy of bevacizumab in cancer. Lancet Oncol 2010, 11:1172-1183.
82. Raja F.A., Hook J.M., Ledermann J.A. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev 2012, [Epub ahead of print].
83. Nimeiri H.S., Oza A.M., Morgan R.J., et al. Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and Fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol 2008, 110:49-55.
84. Han E.S., Burger R.A., Darcy K.M., et al. Predictive and prognostic angiogenic markers in a Gynecologic Oncology Group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer. Gynecol Oncol 2010, 119:484-490.
85. Chambers S.K., Clouser M.C., Baker A.F., et al. Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer. Clin Cancer Res 2010, 16:5320-5328.
86. Bernaards C., Hegde P., Chen D., et al. Circulating vascular endothelial growth factor (VEGF) as a biomarker for bevacizumab-based therapy in metastatic colorectal, non-small cell lung, and renal cell cancers: analysis of phase III studies. J Clin Oncol 2010, 28(15S):10519.
87. Klement G.L., Yip T.T., Cassiola F., et al. Platelets actively sequester angiogenesis regulators. Blood 2009, 113:2835-2842.
88. Schultheis A.M., Lurje G., Rhodes K.E., et al. Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res 2008, 14:7554-7563.
89. Mizukami Y., Jo W.S., Duerr E.M., et al. Induction of interleukin-8 preserves the angiogenic response in HIF-1alpha-deficient colon cancer cells. Nat Med 2005, 11:992-997.
90. Gourley C., Michie C.O., Keating K.E., et al. Establishing a molecular taxonomy for epithelial ovarian cancer (EOC) from 363 formalin-fixed paraffin embedded (FFPE) specimens. J Clin Oncol 2011, 29(15S):5000.
91. Nagengast W.B., De Vries E.G., Hospers G.A., et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007, 48:1313-1319.
92. Nagengast W.B., Lub-De Hooge M.N., Oosting S.F., et al. VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment. Cancer Res 2011, 71:143-153.
93. 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922. J Nucl Med 2010, 51:761-767.
94. Agarwal A., Tressel S.L., Kaimal R., et al. Identification of a metalloprotease-chemokine signaling system in the ovarian cancer microenvironment: implications for antiangiogenic therapy. Cancer Res 2010, 70:5880-5890.
95. Agarwal A., Covic L., Sevigny L.M., et al. Targeting a metalloprotease-PAR1 signaling system with cell-penetrating pepducins inhibits angiogenesis, ascites, and progression of ovarian cancer. Mol Cancer Ther 2008, 7:2746-2757.
96. Merritt W.M., Lin Y.G., Spannuth W.A., et al. Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst 2008, 100:359-372.
97. Rapisarda A., Melillo G. Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 2009, 12:74-80.
98. Nolan D.J., Ciarrocchi A., Mellick A.S., et al. Bone marrow-derived endothelial progenitor cells are a major determinant of nascent tumor neovascularization. Genes Dev 2007, 21:1546-1558.
99. Shojaei F., Wu X., Malik A.K., et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol 2007, 25:911-920.
100. Shojaei F., Wu X., Zhong C., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
101. Zhang L., Yang N., Conejo-Garcia J.R., et al. Expression of endocrine gland-derived vascular endothelial growth factor in ovarian carcinoma. Clin Cancer Res 2003, 9:264-272.
102. Zhang Y., Tang H., Cai J., et al. Ovarian cancer-associated fibroblasts contribute to epithelial ovarian carcinoma metastasis by promoting angiogenesis, lymphangiogenesis and tumor cell invasion. Cancer Lett 2011, 303:47-55.
103. Granot D., Addadi Y., Kalchenko V., Harmelin A., Kunz-Schughart L.A., Neeman M. In vivo imaging of the systemic recruitment of fibroblasts to the angiogenic rim of ovarian carcinoma tumors. Cancer Res 2007, 67:9180-9189.
104. Crawford Y., Kasman I., Yu L., et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 2009, 15:21-34.
105. Dong J., Grunstein J., Tejada M., et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. EMBO J 2004, 23:2800-2810.
106. Lu C., Thaker P.H., Lin Y.G., et al. Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. Am J Obstet Gynecol 2008, 198. 477e1-9.
107. Kuhnert F., Tam B.Y., Sennino B., et al. Soluble receptor-mediated selective inhibition of VEGFR and PDGFRbeta signaling during physiologic and tumor angiogenesis. Proc Natl Acad Sci U S A 2008, 105:10185-10190.
108. Schilder R.J., Sill M.W., Lee R.B., et al. Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2008, 26:3418-3425.
109. Apte S.M., Fan D., Killion J.J., Fidler I.J. Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 2004, 10:897-908.
110. Hirota K., Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit Rev Oncol Hematol 2006, 59:15-26.
111. Franco M., Man S., Chen L., et al. Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. Cancer Res 2006, 66:3639-3648.
112. Ocaňa A., Amir E., Vera F., Eisenhauer E.A., Tannock I.F. Addition of bevacizumab to chemotherapy for treatment of solid tumors: similar results but different conclusions. J Clin Oncol 2011, 29:254-256.
113. Ebos J.M., Lee C.R., Christensen J.G., Mutsaers A.J., Kerbel R.S. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci U S A 2007, 104:17069-17074.
114. Ebos J.M., Lee C.R., Cruz-Munoz W., Bjarnason G.A., Christensen J.G., Kerbel R.S. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
115. Pàez-Ribes M., Allen E., Hudock J., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
116. Yoo Y.G., Christensen J., Huang L.E. HIF-1alpha confers aggressive malignant traits on human tumor cells independent of its canonical transcriptional function. Cancer Res 2011, 71:1244-1252.
117. Seeber L.M., Horrée N., Vooijs M.A., et al. The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol 2011, 78:173-184.
118. Meric-Bernstam F., Gonzalez-Angulo A.M. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009, 27:2278-2287.
119. Altomare D.A., Wang H.Q., Skele K.L., et al. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 2004, 23:5853-5857.
120. Ma X.M., Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009, 10:307-318.
121. Lane H.A., Wood J.M., McSheehy P.M., et al. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor. Clin Cancer Res 2009, 15:1612-1622.
122. Mabuchi S., Altomare D.A., Connolly D.C., et al. RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer. Cancer Res 2007, 67:2408-2413.
123. Mabuchi S., Altomare D.A., Cheung M., et al. RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res 2007, 13:4261-4270.
124. Morgan R., Oza A.M., Qin R., et al. A phase II trial of temsirolimus and bevacizumab in patients with endometrial, ovarian, hepatocellular carcinoma, carcinoid, or islet cell cancer: ovarian cancer (OC) subset-a study of the Princess Margaret, Mayo, Southeast phase II, and California Cancer (CCCP) N01 Consortia NCI#8233. J Clin Oncol 2011, 29(15S):5015.
125. Thomas G.V., Tran C., Mellinghoff I.K., et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med 2006, 12:122-127.
126. Del Buffalo D., Ciuffreda L., Trisciuoglio D., et al. Antiangiogenic potential of the mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 2006, 66:5549-5554.
127. Staufer K., Stoeltzing O. Implication of heat shock protein 90 (HSP90) in tumor angiogenesis: a molecular target for anti-angiogenic therapy?. Curr Cancer Drug Targets 2010, 10:890-897.
128. Vidal C.I., Mintz P.J., Lu K., et al. An HSP90-mimic peptide revealed by fingerprinting the pool of antibodies from ovarian cancer patients. Oncogene 2004, 23:8859-8867.
129. Liu Y.V., Baek J.H., Zhang H., Diez R., Cole R.N., Semenza G.L. RACK1 competes with HSP90 for binding to HIF-1alpha and is required for O(2)-independent and HSP90 inhibitor-induced degradation of HIF-1alpha. Mol Cell 2007, 25:207-217.
130. Eccles S.A., Massey A., Raynaud F.I., et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008, 68:2850-2860.
131. Sanderson S., Valenti M., Gowan S., et al. Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Mol Cancer Ther 2006, 5:522-532.
132. Cohn D.E., Kim K.H., Resnick K.E., O'Malley D.M., Straughn J.M. At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis. J Clin Oncol 2011, 29:1247-1251.
133. Dorrell M.I., Aguilar E., Scheppke L., Barnett F.H., Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci U S A 2007, 104:967-972.
134. Kumar R., Crouthamel M.C., Rominger D.H., et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009, 101:1717-1723.
135. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
136. Wedge S.R., Kendrew J., Hennequin L.F., et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005, 65:4389-4400.
137. Hilberg F., Roth G.J., Krssak M., et al. BIBF 1120 triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008, 68:4774-4782.